Chronic obstructive pulmonary disease (COPD) is a progressive and debilitating disorder, which, as it progresses, places a significant burden on individuals and those caring for them.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
